Clinical relevance of the urokinase plasminogen activator system in breast cancer
- 1 March 1999
- Vol. 107 (1-6) , 150-159
- https://doi.org/10.1111/j.1699-0463.1999.tb01538.x
Abstract
Until recently clinical features and the hormone‐receptor status were the only factors used to select systemic (adjuvant) treatment for breast cancer patients. Other biological factors are needed as well to predict the probability of relapse and response with more certainty. The uPA‐system is such a prognostic and predictive factor in breast cancer. In this review, the results of research groups that have related relapse‐free survival to the quantitative levels of uPA‐system proteins and/or activities are discussed. Only studies that described the results from assays on cytosols or triton extracts of breast tumours were included. The levels of uPA‐system proteins help to predict the probability of relapse and response, and knowledge of the expression levels of the various components of the uPA‐system may lead to new treatment modalities targeted on specific properties of the uPA‐system.Keywords
This publication has 36 references indexed in Scilit:
- A prospective study on the prognostic significance of urokinase-type plasminogen activator levels in breast cancer tissueZeitschrift für Krebsforschung und Klinische Onkologie, 1997
- Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 WorkshopEuropean Journal Of Cancer, 1996
- Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassayEuropean Journal Of Cancer, 1996
- Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancerSurgery, 1995
- Type‐1 plasminogen activator inhibitor in human breast carcinomasInternational Journal of Cancer, 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast CancerSeminars in Thrombosis and Hemostasis, 1991
- Urokinase-plasminogen activator in breast cancerBlood Coagulation & Fibrinolysis, 1991
- Urokinase plasminogen activator and prognosis in breast cancerThe Lancet, 1990
- UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCERThe Lancet, 1989